A Phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280 in patients with unresectable locally advanced or metastatic cancer.

  • Richardson, Gary (Primary Chief Investigator (PCI))
  • Spence, Anne (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date2/05/22 → 31/12/27

Keywords

  • Metastatic cancer
  • Clinical trial